Iron Metabolism in Parkinson's Disease

Parkinson’s disease is characterised by progressive loss of dopaminergic neurons in the substantia nigra, where iron plays a dual role as an essential cofactor and a catalyst for toxic oxidative chemistry. Under normal conditions, iron is imported via transferrin receptor–mediated uptake, stored safely within ferritin and exported by ferroportin. In Parkinson’s disease, dysregulation of these pathways leads to regional iron accumulation, particularly in the nigrostriatal system. Excess ferrous iron participates in Fenton chemistry, generating reactive oxygen species that damage lipids, proteins and DNA. Aberrant iron also promotes misfolding and aggregation of α-synuclein into Lewy bodies, exacerbating mitochondrial dysfunction, neuroinflammation and neuronal death. Contemporary imaging methods such as quantitative susceptibility mapping (QSM) and R2* relaxometry have enabled in vivo mapping of iron deposits and their correlation with motor and cognitive impairment. Emerging fluid assays aim to detect iron-bound protein aggregates in cerebrospinal fluid and blood, offering prospects for early diagnosis and patient stratification.

Research from Nature Portfolio

Recent studies have introduced combined imaging and fluid biomarker approaches to capture iron-related pathology at earlier stages. Novel magnetic resonance techniques sensitive to microstructural composition have demonstrated increased susceptibility signals in the substantia nigra and basal ganglia, which correlate with refined biological staging systems for motor and cognitive decline. Parallel advances in seed-amplification assays and vesicle profiling have revealed iron-associated protein aggregates in cerebrospinal fluid, providing molecular signatures that distinguish clinical subtypes and may guide precision interventions. A foundational meta-analysis integrating postmortem iron measurements and multiple MRI modalities confirmed elevated iron in the substantia nigra, putamen and red nucleus. This work established normative benchmarks for susceptibility mapping and highlighted methodological variances across imaging platforms.

Iron Metabolism in Parkinson's Disease publication trend

The graph below shows the total number of articles in iron metabolism in parkinson's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Quantitative susceptibility mapping (QSM): Magnetic resonance technique quantifying magnetic susceptibility to estimate regional iron content.

Reactive oxygen species: Chemically reactive molecules derived from oxygen that induce oxidative damage.

Ferritin: Protein complex that stores intracellular iron and releases it in a controlled fashion.

Ferroportin: Cellular iron-export protein regulating iron release from cells.

α-Synuclein: Neuronal protein that aggregates into Lewy bodies in Parkinson’s disease.

References

1. Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions. Nature Communications (2024).
2. Meta-analysis of brain iron levels of Parkinson’s disease patients determined by postmortem and MRI measurements. Scientific Reports (2016).
3. Longitudinal Associations of Magnetic Susceptibility with Clinical Severity in Parkinson's Disease. Movement Disorders (2024).
4. Exploring the genetic and genomic connection underlying neurodegeneration with brain iron accumulation and the risk for Parkinson’s disease. npj Parkinson's Disease (2023).